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Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions
related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected by advanced colorectal cancer were treated
with different schedules containing OHP, at the Institute of Haematology and Medical Oncology ‘L. and A. Seragnoli’ of Bologna and
at the Medical Oncology Division of Livorno Hospital. Seventeen patients (13%) showed hypersensitivity reactions after a few
minutes from the start of the OHP infusion. Usually, these reactions were seen after 2–17 exposures to OHP (Mean7s.e.:
9.471.07). No patient experienced allergic reactions at his/her first OHP infusion. Eight patients developed a mild reaction consisting
of flushing and swelling of the face and hands, itching, sweating and lachrymation. The remaining nine patients showed a moderate–
severe reaction with dyspnoea, wheezing, laryngospasm, psycho-motor agitation, tachycardia, precordial pain, diffuse erythema,
itching and sweating. Six patients out of 17 were re-exposed to the drug with premedication of steroids and all except one
developed the hypersensitivity reaction again. The cumulative dose, the time of exposure to OHP and the clinical features are
variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot
be underestimated.
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Oxaliplatin (OHP) is the most recent platinum compound entering
the clinical practice. It is an alkylating agent on DNA and forms
DACH-platinum DNA adducts more hydrophobic than those
formed by cisplatin (CDDP) and carboplatin (CBDCA). It is
effective in advanced colorectal cancer both as a first-line therapy
and in 5-fluorouracil (5-FU) refractory patients (Bertheault-
Cvitkovic et al, 1996; De Gramont et al, 1997; Andre’ et al, 1999;
Maindrault-Goebel et al, 1999).
OHP is less nephro-ototoxic than CDDP and less mielotoxic
than CBDCA (Misset 1998). The most characteristic and dose-
limiting toxicity of OHP is sensory neuropathy, which is dose
cumulative and schedule related. It is clinically characterised by a
transient acute cold-related dysaesthesias, sometimes pain-asso-
ciated, or with cramps and functional failure, although it is
generally reversible (Caussanel et al, 1990, Misset, 1998).
Hypersensitivity reactions to oxaliplatin have been described only
sporadically.
For other platinum compounds, this kind of reaction is well
known (Cleare et al, 1976; Wiesenfeld et al, 1979; Planner et al,
1991; Morgan et al, 1994; Weideman et al, 1994; Shleback et al,
1995; Markman et al, 1999; O ¨zgu ¨roglu et al, 1999). On data
sheets of OHP, these clinical features are not stressed. In fact,
only the main severe form of hypersensitivity, that is to say
anaphylaxis, is reported in 0.5% of patients treated. This reaction
is clinically characterised by laryngospasm and wheezing and
immunologically linked to the release of histamine and other vaso-
active substances.
As a result of the increasing use of OHP in colorectal cancer, we
have found frequent hypersensitivity reactions. In this study, we
report the epidemiological and clinical features of these reactions,
as well as their management.
MATERIALS AND METHODS
From February 1999 to February 2002 at the Institute of
Haematology and Medical Oncology ‘L. and A. Seragnoli’ of
Bologna and at the Medical Oncology Division of Livorno, 124
outpatients with advanced colorectal cancer were treated with
OHP-based therapies. Eighty-four out of 124 patients (67.7%)
received OHP as a first-line treatment. Fifty-five patients (44.3%)
were treated with a FOLFOX-4 regimen (Andre’ et al, 1999;
De Gramont et al, 2000), 34 patients (27.4%) with FOLFOX-3
regimen (De Gramont et al, 1999), 30 patients (24.1%)
with the association of OHP/CPT-11/c.i.5-FU/FA regimen
(Falcone et al, 2002), three patients (2.4%) with OHP alone
(Diaz-Rubio et al, 1998) and two patients (1.6%) with OHP/
Raltitrexed regimen (Seitz et al, 1999). All patients received a
standard antiemetic treatment with ondansetron 8mg by a i.v.
administration before chemotherapy. We did not use dexametha-
sone in this population.
Major sites of metastases were the liver, lungs and peritoneum.
Among these patients, 17 out of 124 (13.7%) reported a
hypersensitivity reaction attributable to OHP. There were
eight males and nine female patients, with a mean age of
60.3 years (range 37–76). In 11 out of 17 patients with
hypersensitivity reaction, OHP was administered in first-line
chemotherapy. Received 8 July 2002; revised 22 April 2003; accepted 25 May 2003
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lRESULTS
Results are shown in Table 1. The reaction occurs after a
mean7s.e.¼9.471.07 infusions of chemotherapy (range 2–17).
Only two patients experienced early hypersensitivity at the second
and third infusion, respectively.
On average, there were 217.7732.5 days (mean7s.e.) (range
74–575) between the first exposure to OHP and the reaction.
Eight out of 124 (6.5%) patients reported only erythema and
itching of the palms and flushing of the face and hands after the
beginning of OHP infusion. Nine out of 124 (7.3%) patients
developed a more severe reaction with dyspnoea, wheezing,
Table 1 Patients with hypersensitivity reactions
Case
Sites of
metastases
Chemotherapy
regimen
Infusion number
at reaction
Total dose
of OHP (mg)
Clinical features
of reaction
Length of
reaction (min)
Treatment of
reaction
Re-exposure to
OHP with
premedication
and outcome
1 Lung FOLFOX-4 3 382 Bronchospasm 7 days Hospitalisation/high
dose of steroid
No
Laryngospasm
Dyspnoea
2 Peritoneum FOLFOX-4 14 2100 Bronchospasm 60 Oxygen No
Dyspnoea Steroids
Hand oedema Antihistaminic
Eriythema
3 Liver Oxaliplatin 10 2070 Bronchospasm 50 Steroids No
Dyspnoea
Hypotension
4 Liver FOLFOX-3 17 2271 Dyspnoea 5–10 Steroids Yes, with reaction
Lung Hand, face oedema Antihistaminic
Erythema, itching
Psychomotor agitation
5 Peritoneum Oxalipatin 2 360 Dyspnoea 120 Steroids No
Laryngospasm Antihistaminic
6 Liver Irinotecan 11 1620 Dyspnoea 15–20 Steroids No
Oxaliplatin Eye oedema Antihistaminic
Fluorouracil Face erythema
Folinic acid Itching
Sweating
7 Liver FOLFOX-3 17 2720 Dyspnoea 15–20 Steroids Yes, with reaction
Lung Oedema Antihistaminic
Erythema
Sweating
Lachrymation
8 Liver FOLFOX-4 6 900 Dyspnoea 30 Steroids No
Erythema Antihistaminic
Itching
Mouth oedema
9 Liver FOLFOX-4 8 1120 Dyspnoea 60 Steroids No
Lung Hand, face erythema Antihistaminic
10 Liver FOLFOX-4 8 1360 Erythema, 15–20 Steroids No
Tachycardia Antihistaminic
Precordial pain
Pruritus
11 Peritoneum FOLFOX-4 9 630 Hand oedema,
Hand genital itching
20 Antihistaminic Yes, without reaction
Hand, face erythema
12 Peritoneum FOLFOX-4 5 940 Hand face erythema 20–30 Antihistaminic No
Hand oedema
Hand itching
13 Liver Irinotecan 14 2600 Itching 15–20 Steroids Yes, with reaction
Peritoneum Oxaliplatin Sweating Anthistaminic
Fluorouracil Lachrymation
Folinic acid Face oedema,
Face erythema
14 Liver FOLFOX-4 7 1040 Face, chest erythema 120 Steroids Yes, with reaction
Itching Antihistaminic
15 Liver FOLFOX-4 13 1705 Face, chest erythema 50 Steroids No
Peritoneum Shiver without fever Antihistaminic
Tremor
16 Diaphragm FOLFOX-4 8 1080 Arms, chest erythema 50 Steroids Yes, with reaction
With pomphoid reaction
17 Peritoneum FOLFOX-3 9 1377 Sweating 15–20 Steroids No
Erythema
Hypotension
Nausea
Oxaliplatin’s hypersensitivity
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llaryngospasm, psico-motor agitation, tachycardia, precordial pain,
diffuse erythema, itching and sweating. Only two patients
experienced the symptoms at the end of the infusion, while the
others developed the reaction between 10 to 15min from the start
of OHP infusion. All patients showing hypersensitivity were
treated with steroids, many of them in association with
antihistaminic drugs. The symptoms disappeared within half an
hour to 2h after stopping the OHP infusion and the beginning of
the antiallergic therapy. One patient required hospitalisation for
dyspnoea that disappeared in a few days.
Once the reaction had disappeared, nine patients continued the
scheduled drug infusions, in particular 5-fluorouracile (5-FU) and
Folinic acid, without any additional problem.
The percentage of reaction is different according to the
chemotherapy regimens employed: 66.6% for OHP alone, 18.1%
for FOLFOX-4 regimen, 8.8% for FOLFOX-3 regimen and 6.6% for
OHP/CPT-11/c.i.5-FU/FA regimen (Table 2).
Three patients developed the reaction to the first chemotherapy
treatment after a long period of rest. The total administered doses
of OHP in patients developing the reaction are reported in Table 1.
The cumulative dose of OHP was 1428mg7176.7 (mean7s.e.)
(range 360–2720mg).
Six out of 17 patients with hypersensitivity reactions were
successively re-exposed to OHP chemotherapy after premedication
with steroids and antihistaminic drugs. Five of these six patients
developed the same symptoms again, while one patient had no
further reaction.
DISCUSSION
Hypersensitivity reactions to platinum compounds are a well-
known phenomena (Weiss, 1992). In the 1950s, literature reported
the capacity of platinum salts to induce bronchial asthma among
platinum-refinery workers (Hunter et al, 1945). It is not surprising
that after the introduction of platinum compounds into che-
motherapy, their association with type I hypersensitivity reactions
was confirmed (Cleare et al, 1976). These reactions were first
described for CDDP with a 5–20% incidence (Wiesenfeld et al,
1979; Shleback et al, 1995; O ¨zgu ¨roglu et al, 1999), and evidence
regarding similar reactions for CBDCA are also available (Planner
et al, 1991; Morgan et al, 1994; Weideman et al, 1994; Markman
et al, 1999).
This kind of toxicity has been sporadically reported in clinical
trials focusing on the effectiveness of OHP in chemotherapy or
described as case reports (Machover et al, 1996; Diaz Rubio et al,
1998; Tournigand et al, 1998; Larzilliere et al, 1999; Medioni et al,
1999; De Gramont et al, 2000; Dold et al, 2002; Monnet et al, 2002).
Our results support the assumption that this side effect should
not be underestimated. More than 13% of OHP-treated patients
developed hypersensitivity reaction. This phenomenon is not well
known, probably because OHP entered clinical practice only a few
years ago. Moreover, according to our experience, the reactions
generally develop after about 9–10 infusions. The relationship
between the hypersensitivity reaction and OHP is supported by the
following evidence. First, the symptoms developed a few minutes
after starting the OPH infusion; secondly, the patients re-exposed
to successive OHP administration developed a similar reaction;
thirdly, two patients developed a reaction after monochemother-
apy OHP infusion; finally, in patients treated with OHP/CPT-11/c.i.
5-FU/FA regimen, the reaction could be confused with a
cholinergic syndrome due to CPT-11, but the responsibility of
CPT-11 can be excluded since the re-exposure to CPT-11/c.i. 5-FU/
FA without OHP was not able to provoke the hypersensitivity
reaction.
The pathophysiology of hypersensitivity reactions is not clear,
but the finding that almost all patients developed the reaction after
multiple infusions of treatment suggests the need to be sensitised
during previous cycles. Symptoms usually develop early after the
start of the infusion and have been ascribed to a type I
hypersensitivity Ig-E-mediated reaction (Stahl et al, 2001).
A different hypothesis suggests that platinum salts could induce
an oligo or polyclonal T-cells expansion. These compounds can act
as a superantigen on the peripheral blood mononuclear cells, thus
releasingalargeamountofproinflammatorycytokines(IL-6,TNFa,
g interferon) (Santini et al, 2001). The other possible mechanism
consists in binding the platinum salts to different peptides of
major histocompatibility complex (MHC).
In fact, HLA phenotype is a significant determinant of
occupational sensitisation to inhaled hapten of complex platinum
salts and the strength of this association varies according to the
intensity of exposure (Newman Taylor et al, 1999).
Furthermore, the relationship between hypersensitivity reac-
tions and HLA-haplotype has been described for other drugs
(Hetherington et al, 2002). Additional factors are deemed to be
necessary to the immune system for developing the reaction after
several infusions.
Apart from hypersensitivity-related dyspnoea and wheezing, the
lung may also be the target of a particular toxicity. A patient
treated with OHP-5FU therapy developed severe dyspnoea. A
bronchus alveolar lavage (BAL) and a lung biopsy diagnosed a
diffuse alveolar damage that disappeared with steroid therapy
(Trisolini et al, 2001).
In our experience, when a hypersensitivity reaction occurred,
the infusion of OHP was immediately stopped and replaced by a
saline infusion, an intravenous antihistaminic drug and a low-dose
corticosteroids administration. In the case of more severe
reactions (dyspnoea, sweating, bronchospasm, laryngospasm), we
immediately administered a high dose of steroid. The steroid dose
ranged between 100 and 1000mg of hydrocortisone. After the
reaction disappeared, the OHP infusion was not restarted and the
decision to administer the other scheduled drugs was taken
evaluating the clinical status of the patient after the reaction, the
risk of additional toxicity and the clinical utility of the
chemotherapy. In this way, about two-thirds of patients (11
patients) continued the infusion of other planned antiblastic drugs
without any additional clinical problems.
In order to avoid further hypersensitivity problems in successive
cycles, one can presumably explore a maximum prophylactic
immunological blockage with a high dose of steroids and
antihistaminic drugs for several days before the infusion of OHP,
but the real benefit is uncertain because five out of six patients
Table 2 Number of reactions according to the regimen
Chemotherapy
regimen
No. of
patients
No. of
reactions
% reaction according to
the regimen
Mean no. of infusions
at the reaction onset
FOLFOX-4 55 10 18.1 8.1
FOLFOX-3 34 3 8.8 14.3
Irinotecan Oxaliplatin
Fuorouracil Folinic acid
30 2 6.6 12.5
Oxaliplatin 3 2 66.6 6
Oxaliplatin’s hypersensitivity
G Brandi et al
479
British Journal of Cancer (2003) 89(3), 477–481 & 2003 Cancer Research UK
C
l
i
n
i
c
a
ltreated with steroids and/or antihistaminic drugs immediately
before re-exposure developed the same intensity of reaction.
Documented data suggest that OHP as a continuous 6-h infusion
seems to decrease the risk of hypersensitivity reactions. Only one
out of 100 (1%) patients treated with OHP as a 6-h infusion added
to chronomodulated 5-FU–FA as a first-line treatment of
advanced colorectal cancer developed hypersensitivity-like reac-
tions (Giacchetti et al, 2000). When OHP is infused in a
chronomodulate setting (as a 12-h infusion) or flat infusion for 5
days, these hypersensitivity reactions do not occur. In particular,
151 patients submitted to 1087 constant rate continuous infusion
courses of OHP, and 491 patients submitted to 3106 chronomo-
dulate OHP courses did not experience any hypersensitivity
reactions (Caussanel et al, 1990; Levi et al, 1992, 1993, 1994b,
1997, 1999; Bertheault-Cvitkovic et al, 1996).
Therefore, the incapacity of these schedules to produce
hypersensitivity might be due to a long time infusion rather than
to failure of activation of the immune system (which presents a
circadian rhythm) in a chronomodulate setting (Levi et al, 1994a).
Interestingly, five patients who developed hypersensitivity
reactions to 2-h OHP infusion, when re-exposed to 6-h OHP
infusion, did not show any symptoms (Maindrault-Goebel et al,
2001). The mechanism is still unclear, although it is supposed that
the maximum concentration reached by the drug is lower in a
longer time of infusion. Theoretically this situation might occur
with increased hydration, but no data are available. In the adjuvant
setting, the number of allergic reactions is different from the
advanced disease. In fact only 2% of the allergic, not already
specified, reactions have been reported (De Gramont et al, 2002).
The reason for this important difference is unclear.
It could be possible that the tumour releases factors able to
make the immune system more sensitive, but no data are available.
In our study, neither the cumulative dose of OHP nor the lapse
of time between the first exposition and the reaction are able to
predict the hypersensitivity reaction. In our experience, the
severity of clinical symptoms is variable and we cannot identify
the patients at risk of developing the reaction or the factors
indicating the patients where the reaction could be more severe.
Particular attention is necessary when the lung is the target of
reaction, because the re-exposure to OHP generally affects the
same site with higher intensity. Special care is mandatory in
patients receiving OHP for a long time and/or re-exposing to OHP
after a pause.
In conclusion, a late hypersensitivity reaction seems a limiting
toxicity of OHP administered in 2h, and in patients previously
affected it is advisable to avoid readministration of OHP with the
same short schedule.
Literature data suggest that long-term OHP infusions are able to
prevent the hypersensitivity reaction. The use of steroids does not
seem useful in preventing hypersensitivity in patients having
experienced previous reactions. On the contrary, long-term
infusions, without dose decreasing, may prevent this reaction in
patients previously affected, but a larger number of cases are
required to provide definite responses on this matter.
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